PMLiVE5d
AbbVie’s continuous Parkinson’s disease therapy Vyalev approved by FDA
AbbVie’s Parkinson’s disease (PD) therapy has been approved by the US Food and Drug Administration (FDA) to treat motor ...
PMLiVE8d
Innovative Trials appoints new Leadership Team member
Patient Recruitment company, Innovative Trials, appointed new Finance and Business Services Director Innovative Trials have ...
PMLiVE7d
Inizio Medical appoints Matt Wadyka as president, US medical affairs
Inizio Medical has announced the appointment of Matt Wadyka as president, US medical affairs. In this newly created role, ...
PMLiVE7d
J&J’s nipocalimab shows sustained disease control in adolescents with generalised myasthenia gravis
Johnson & Johnson’s (J&J) investigational FcRn blocker nipocalimab has demonstrated sustained disease control in adolescents with the rare autoimmune disease generalised myasthenia gravis (gMG), ...
PMLiVE23h
Atkinson Brand Reaction
Integration and creativity are at the core of our healthcare approach. Aided by our consumer driven insight, derived from our experience outside healthcare, we add an extra dimension in a regulated ...
PMLiVE12d
Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval
Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare products ...
PMLiVE14d
Merck’s Keytruda shows promise as perioperative head and neck cancer treatment
Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...
PMLiVE19d
Bristol Myers Squibb’s Opdivo regimen granted FDA approval in NSCLC
Bristol Myers Squibb’s Opdivo (nivolumab) has been approved by the US Food and Drug Administration (FDA) as part of a perioperative treatment regimen for adults with non-small cell lung cancer (NSCLC) ...
PMLiVE12d
Roche’s Itovebi combination granted FDA approval for advanced breast cancer
Roche’s PI3K inhibitor Itovebi (inavolisib) has been approved by the US Food and Drug Administration (FDA) as part of a combination treatment for advanced breast cancer. The drug has been authorised ...
PMLiVE9d
Pfizer shares positive phase 3 results for Talzenna combination in prostate cancer
Pfizer has announced positive overall survival (OS) results from a late-stage study of its prostate cancer combination treatment. The phase 3 TALAPRO-2 trial has been evaluating the drugmaker’s PARP ...
PMLiVE8d
FDA advisory committee recommends Stealth’s elamipretide for Barth syndrome
A US Food and Drug Administration (FDA) panel of experts has voted in support of Stealth BioTherapeutics’ elamipretide for Barth syndrome, an ultra-rare genetic disease that affects approximately 150 ...
PMLiVE13d
PM Society Awards 2025 open for entries
You can now start working on your entries and don’t forget to get them to us by Thursday 14 November by midnight to qualify for our early bird pricing. Entry deadline is Thursday 21 November and a ...